EIKN
Eikon Therapeutics, Inc.
Key Financials
Net Income
$-82958000
N/A
Operating Income
$-87337000
N/A
Total Assets
$850.8M
N/A
EPS (Diluted)
$-2.46
N/A
Cash & Equivalents
$161.2M
N/A
Shareholders' Equity
$550.7M
N/A
Total Liabilities
$300.2M
N/A
Operating Cash Flow
$-89801000.00
N/A
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 3 | 6/15/2026 | View on SEC |
| 8-K | 6/10/2026 | View on SEC |
| 8-K | 6/1/2026 | View on SEC |
| SCHEDULE 13G | 5/15/2026 | View on SEC |
| SCHEDULE 13G | 5/13/2026 | View on SEC |
| 10-Q | 5/11/2026 | View on SEC |
| 8-K | 5/11/2026 | View on SEC |
| SCHEDULE 13G | 5/6/2026 | View on SEC |
| SCHEDULE 13G | 4/29/2026 | View on SEC |
| 8-K | 3/30/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | EIKN |
| Company Name | Eikon Therapeutics, Inc. |
| CIK | 1861123 |
| Sector | Biological Products, (No Diagnostic Substances) |
| Industry | Emerging growth company |
| Exchange | Nasdaq |
| SIC Code | 2836 |
| SIC Description | Biological Products, (No Diagnostic Substances) |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 341-777-0566 |